PF-07976016 + midazolam

This is a **combination of PF-07976016 and midazolam** used in drug-drug interaction studies. **PF-07976016** is an oral small molecule antagonist of the gastric inhibitory polypeptide receptor (GIPR), developed by Pfizer for obesity and weight management. It is in early clinical evaluation (Phase 1/2) for obesity and is designed to modulate metabolic pathways by antagonizing GIPR, which is implicated in energy balance and weight control[1][2][4][10]. **Midazolam** is a well-known benzodiazepine, most commonly used as a clinical probe substrate for cytochrome P450 3A (CYP3A) activity in pharmacokinetic interaction studies. This specific combination—administering PF-07976016 with midazolam—serves to evaluate if PF-07976016 affects the pharmacokinetics of midazolam, primarily to assess CYP3A-mediated drug-drug interaction potential[2]. The combination is not intended as a therapeutic regimen but for study of metabolic interactions in clinical pharmacology research settings.